CD274 and neoplasm: The greater the number of infiltrating T lymphocytes, the stronger the local immune response, and the better the prognosis.[14] In addition, approximately 30% of EC patients have mismatch repair defects or high microsatellite instability (MSI-H), these EC patients are potential beneficiaries of PD-1/PD-L1 inhibitor therapy.[15] Tumor vaccines targeting neoantigens are also of interest as an immunotherapy method that can effectively induce tumor-specific T cells in patients to exert anti-tumor effects without killing normal cells.